Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (321-330 of 358) with videos related to

Pageof 36
Sort By:
The New Microbiologica|January 4, 2019
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected personsAndrea Antinori, Antonio Di Biagio, Simone Marcotullio, et al.
The New Microbiologica|May 27, 2014
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodologySimone Marcotullio, Adriana Ammassari, Massimo Andreoni, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Biomedicines|May 27, 2023
COVID-19: A Possible Contribution of the MAPK PathwayJessica Cusato, Alessandra Manca, Alice Palermiti, et al.
Cancers|January 24, 2019
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with NivolumabJessica Cusato, Carlo Genova, Cristina Tomasello, et al.
British Journal of Clinical Pharmacology|September 17, 2022
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIVMicol Ferrara, Jessica Cusato, Elena Salvador, et al.
The Journal of Infectious Diseases|April 19, 2008
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failureValentina Svicher, Stefano Aquaro, Roberta D'Arrigo, et al.
Antioxidants (Basel, Switzerland)|January 25, 2025
How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWHJessica Cusato, Anna Mulasso, Micol Ferrara, et al.
AIDS (London, England)|February 26, 2021
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIVGiovanni Guaraldi, Stefano Calza, Jovana Milic, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Pageof 36

Showing results (321-330 of 358) with videos related to

Sort By:
Pageof 36
The New Microbiologica|January 4, 2019
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected personsAndrea Antinori, Antonio Di Biagio, Simone Marcotullio, et al.
The New Microbiologica|May 27, 2014
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodologySimone Marcotullio, Adriana Ammassari, Massimo Andreoni, et al.
BMC Infectious Diseases|July 16, 2005
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti, Giuseppe Lapadula, Salvatore Casari, et al.
Biomedicines|May 27, 2023
COVID-19: A Possible Contribution of the MAPK PathwayJessica Cusato, Alessandra Manca, Alice Palermiti, et al.
Cancers|January 24, 2019
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with NivolumabJessica Cusato, Carlo Genova, Cristina Tomasello, et al.
British Journal of Clinical Pharmacology|September 17, 2022
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIVMicol Ferrara, Jessica Cusato, Elena Salvador, et al.
The Journal of Infectious Diseases|April 19, 2008
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failureValentina Svicher, Stefano Aquaro, Roberta D'Arrigo, et al.
Antioxidants (Basel, Switzerland)|January 25, 2025
How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWHJessica Cusato, Anna Mulasso, Micol Ferrara, et al.
AIDS (London, England)|February 26, 2021
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIVGiovanni Guaraldi, Stefano Calza, Jovana Milic, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Pageof 36